Illumina, Inc. (ILMN)
EU top court backs Illumina fight against EU probe into Grail deal
Europe's top court on Tuesday backed U.S. gene sequencing company Illumina's fight against EU antitrust regulators' investigation into its $7.1 billion bid for cancer diagnostic test maker Grail.
ILMN's TSO Comprehensive IVD Test Secures FDA Approval as CDx
Illumina's cancer biomarker test, TSO Comprehensive, gets approved by the FDA for use as CDx to match patients with targeted therapies.
Is the Options Market Predicting a Spike in Illumina (ILMN) Stock?
Investors need to pay close attention to Illumina (ILMN) stock based on the movements in the options market lately.
Illumina Sees The Light: GRAIL Is Gone, Focus Restored (Rating Upgrade)
Illumina completed the spin-off of GRAIL in June 2024, retaining a 14.5% stake. The company is refocusing on its core DNA sequencing business, targeting high single-digit revenue growth by 2027. Q2 2024 results showed a gross margin of 68% and a net loss of $1.988 billion, mainly due to impairments.
Illumina Looks Bullish (Technical Analysis)
ILMN has shown bullish signs with price action improving, above 30-week EMA, and potential for trend change. Volume analysis indicates institutional buying, momentum is short-term bullish, and long-term momentum may soon turn bullish. Relative strength has improved since June, suggesting ILMN is outperforming the SP 500 index, making it a potential buy opportunity.
Illumina, Inc. (ILMN) Illumina 2024 Strategy Update Special Call
Illumina, Inc. (NASDAQ:ILMN ) Illumina 2024 Strategy Update Special Call August 13, 2024 11:00 AM ET Company Participants Salli Schwartz - Head of IR Jacob Thaysen - CEO Steve Barnard - CTO Ankur Dhingra - CFO Conference Call Participants Operator Salli Schwartz Thank you for joining us today. My name is Salli Schwartz and I'm Illumina's Head of Investor Relations.
Illumina, CRISPR-pioneer Broad Institute to work on new gene sequencing kits
Illumina said on Tuesday it has partnered with the Broad Institute to develop new kits that will allow large-scale gene sequencing using a novel method based on the Nobel Prize-winning CRISPR technology.
Understanding Illumina (ILMN) Reliance on International Revenue
Evaluate Illumina's (ILMN) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Illumina (ILMN) Beats on Q2 Earnings, Lowers 2024 Sales View
Illumina's (ILMN) Q2 earnings and revenues surpass estimates in a challenging global macroeconomic environment.
Illumina, Inc. (ILMN) Q2 2024 Earnings Call Transcript
Illumina, Inc. (NASDAQ:ILMN ) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Salli Schwartz - Vice President of Investor Relations Jacob Thaysen - Chief Executive Officer Ankur Dhingra - Chief Financial Officer Conference Call Participants Vijay Kumar - Evercore ISI Conor McNamara - RBC Capital Markets Patrick Donnelly - Citi Doug Schenkel - Wolfe Research Dan Arias - Stifel Tycho Peterson - Jefferies Subha Nambi - Guggenheim Securities Puneet Souda - Leerink Partners Sung Ji Nam - Scotiabank Eve Burstein - Bernstein Research David Westenberg - Piper Sandler Dan Brennan - TD Cowen Operator Good day ladies and gentlemen and welcome to the Second Quarter 2024 Illumina Earnings Conference Call. At this time, all participants are in a listen-only mode.
Compared to Estimates, Illumina (ILMN) Q2 Earnings: A Look at Key Metrics
The headline numbers for Illumina (ILMN) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Illumina (ILMN) Q2 Earnings and Revenues Top Estimates
Illumina (ILMN) came out with quarterly earnings of $0.36 per share, beating the Zacks Consensus Estimate of $0.12 per share. This compares to earnings of $0.32 per share a year ago.
